Pediatrix Medical Group (NYSE:MD) Price Target Lowered to $16.00 at Truist Financial

Pediatrix Medical Group (NYSE:MD) had its target price reduced by Truist Financial from $18.00 to $16.00 in a research note issued to investors on Friday morning,Benzinga reports. Truist Financial currently has a hold rating on the stock.

MD has been the subject of a number of other research reports. StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 22nd. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the company a “neutral” rating in a research note on Friday, February 21st. Finally, Macquarie initiated coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price on the stock. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Pediatrix Medical Group presently has a consensus rating of “Hold” and an average target price of $16.75.

Pediatrix Medical Group Stock Down 1.5 %

MD opened at $13.35 on Friday. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $17.67. The company has a market cap of $1.15 billion, a PE ratio of -11.13, a price-to-earnings-growth ratio of 1.74 and a beta of 1.32. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. The company has a 50 day moving average of $14.33 and a 200 day moving average of $13.93.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Thursday, February 20th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.12. The firm had revenue of $502.36 million for the quarter, compared to the consensus estimate of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. On average, sell-side analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current year.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in Pediatrix Medical Group by 4,530.0% in the 1st quarter. GAMMA Investing LLC now owns 37,225 shares of the company’s stock worth $539,000 after buying an additional 36,421 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Pediatrix Medical Group by 0.9% during the 4th quarter. California State Teachers Retirement System now owns 80,327 shares of the company’s stock worth $1,054,000 after acquiring an additional 752 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Pediatrix Medical Group during the 4th quarter worth $276,000. PharVision Advisers LLC purchased a new position in Pediatrix Medical Group in the fourth quarter worth $245,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Pediatrix Medical Group by 7.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 256,335 shares of the company’s stock valued at $3,363,000 after acquiring an additional 18,627 shares during the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.